TB-500 + BPC-157
A combined 1:1 research blend containing BPC-157 10 mg and TB-500 10 mg, studied for complementary effects on tissue-repair signalling, cell migration, angiogenesis and connective-tissue regeneration.
This selector presents the PHONYX research format. It does not initiate a purchase and must not be interpreted as a dose.
Interested in this compound?
Contact the PHONYX team for availability and catalogue information.
What is the TB-500 + BPC-157 blend?
This formulation combines two widely discussed regenerative research peptides in a single 1:1 lyophilized blend. BPC-157 is investigated for tissue protection, angiogenesis, fibroblast activity and gastrointestinal cytoprotection. TB-500 is investigated for actin-associated cell migration, tissue remodelling and mobility-related recovery models.
The combination is studied because the two peptides affect different but potentially complementary repair pathways. Research interest includes muscle, tendon, ligament, joint, skin and connective-tissue models, as well as recovery following physical stress or experimental injury.
Complementary regenerative signalling
BPC-157 component
Research links BPC-157 with VEGF/VEGFR2 signalling, nitric-oxide pathways, fibroblast migration, collagen organization and local tissue protection.
TB-500 component
TB-500 is investigated in relation to actin regulation, cellular migration, tissue remodelling and recovery-associated mobility pathways.
Combined research rationale
The blend is designed to examine whether angiogenic, cytoprotective and cell-migration pathways can provide complementary effects in the same experimental model.
Areas of research interest
Musculoskeletal Muscles, tendons and ligaments
The combination is discussed in research contexts involving tissue recovery after mechanical stress, tendon injury, ligament damage and muscle trauma.
Joint function Mobility and connective tissue
Research interest includes inflammatory signalling, joint mobility and functional recovery in experimental connective-tissue models.
Skin and wounds Tissue closure and regeneration
Both components are associated with pathways involved in cell migration, blood-vessel signalling and tissue remodelling.
Evidence limitation Combination-specific data
Most published evidence evaluates the individual peptides or related biological pathways. Controlled human evidence for the fixed blend remains limited.
Protocol formats for the combined 1:1 blend
Conservative blend protocol
250 mcg total blend per day, commonly represented once daily for approximately 4 weeks.
Standard blend protocol
250–400 mcg total blend per day, commonly represented once daily for 4–8 weeks.
Higher research range
500–1000 mcg total blend per day, corresponding to equal quantities of both components in the 1:1 mixture.
| Blend protocol | Total blend amount | Approximate amount of each component | Typical duration |
|---|---|---|---|
| Conservative | 250 mcg/day | 125 mcg BPC-157 + 125 mcg TB-500 | Approximately 4 weeks |
| Standard | 250–400 mcg/day | 125–200 mcg of each component | 4–8 weeks |
| Common higher range | 500–1000 mcg/day | 250–500 mcg of each component | Up to 8 weeks |
How to interpret the 20 mg vial
Research outcomes associated with the combined pathways
Muscle and tendon models
Research interest centres on recovery signalling following strain, trauma and repetitive physical load.
Cellular movement
TB-500-related pathways are associated with actin regulation and movement of repair-associated cells.
Local blood supply
BPC-157-related pathways are associated with VEGF, nitric oxide and new-vessel signalling.
Joint and connective tissue
The blend is investigated for functional recovery and mobility-related outcomes in experimental models.
Reported observations and limitations
Research-oriented sources commonly describe good tolerability, with infrequent mild observations such as temporary local discomfort or short-lived sensitivity at the administration site. However, controlled human safety data for the fixed combination are limited.
Long-term safety, immunogenicity, interactions, angiogenesis-related risks and the systemic effects of combined exposure remain insufficiently characterized. Material identity, purity, sterility and endotoxin burden are separate quality considerations.
Two peptides with different biological profiles
BPC-157 and TB-500 have distinct sequences and research mechanisms. Their combined pharmacokinetics have not been established in controlled human studies. The 1:1 vial ratio ensures equal mass quantities, but it does not imply identical biological persistence or tissue distribution.
PHONYX portfolio format
Evidence behind the component mechanisms
Frequently asked questions
What does the blend contain?
It contains 10 mg of TB-500 and 10 mg of BPC-157, for 20 mg total material in a 1:1 ratio.
Why are the two peptides combined?
The blend is designed to study complementary repair pathways involving angiogenesis, cytoprotection, actin regulation and cellular migration.
What protocol range is commonly reported for the blend?
Research-oriented sources commonly describe 250–400 mcg total blend daily for up to eight weeks, with some sources describing 500–1000 mcg total blend daily.
Does 400 mcg of blend mean 400 mcg of each peptide?
No. In a 1:1 blend, 400 mcg total contains approximately 200 mcg of each component.
Is 20 mg a single dose?
No. It is the total vial content and must not be interpreted as one administration.
Which tissues are commonly studied?
Muscles, tendons, ligaments, joints, skin and other connective tissues are common research areas.
Is the fixed blend clinically approved?
No. It is not an approved medicinal product, and controlled human evidence remains limited.
How is the blend stored after reconstitution?
Research sources generally describe refrigerated storage at 2–8°C under controlled laboratory conditions.
Are the effects of the blend proven to be synergistic?
The synergy is a research hypothesis based on complementary mechanisms; it has not been established by large controlled human trials.
Does evidence for the individual peptides validate the blend?
No. Evidence for each component does not automatically establish the safety or efficacy of the fixed combination.
Research Disclaimer
This compound is presented exclusively for laboratory and scientific research. It is not intended for human consumption, self-administration, diagnostic use, treatment, cure or prevention of disease. Information describing research protocols is provided for documentary and educational context only and must not be interpreted as medical advice, a dosing recommendation or instructions for use. The fixed TB-500 + BPC-157 combination is not an approved medicinal product, and its clinical safety and efficacy remain unestablished.